Skip to main content

Table 1 Baseline characteristics

From: Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial

Baseline characteristics Treatment group
ASMQ + Pq CQ + Pq AL + Pq
N (%) 88 (33.3%) 88 (33.3%) 88 (33.3%)
Study site
 CEPEM 66 (75.0%) 66 (75.0%) 66 (75.0%)
 FMT-HVD 22 (25.0%) 22 (25.0%) 22 (25.0%)
Gender
 Female 32 (36.4%) 22 (25.0%) 24 (27.3%)
 Male 56 (63.6%) 66 (75.0%) 64 (72.7%)
Age (years)
 > 59 3 (3.4%) 4 (4.5%) 3 (3.4%)
 18–39 45 (51.1%) 34 (38.6%) 49 (55.7%)
 39–59 40 (45.4%) 50 (56.8%) 36 (40.9%)
Weight (kg)
 > 80 25 (28.4%) 22 (25.0%) 27 (30.7%)
 50–65 27 (30.7%) 21 (23.9%) 23 (26.1%)
 65–80 36 (40.9%) 45 (51.1%) 38 (43.2%)
Fever
 < 37.5 48 (54.5%) 54 (61.4%) 53 (60.2%)
 > 37.5 40 (45.4%) 34 (38.6%) 35 (39.8%)
Weight (kg) 71.59 (10.99)
[51–90]
72.7 (10.34)
[53–90]
72.53 (10.59)
[50–90]
Temperature 37.45 (1.38)
[34.7–40.5]
37.31 (1.21)
[35.0–39.9]
37.38 (1.22)
[35.2–40.6]
Parasitaemia 2145 (2516.4)
[258–13,340]
2155 (2908.5)
[285–17,680]
2444 (3974.6)
[270–20,080]
Age (years) 38.75 (10.9)
[19.5–65.8]
41.88 (10.5)
[19.7–64.9]
37.24 (11.8)
[18.4–64.3]
  1. Absolute number and percentage (%) were used to present categorical variables. Quantitative data presented using means, standard deviations (SD), and ranges [min–max]. Parasitaemia presented using geometric mean